Yahoo Finance Tesla Stock Is Up. Here’s Where It’s Headed.
Shares of electric-vehicle maker Tesla dropped 4.4% on Thursday, leaving shares down almost 8% for the week.
Shares of electric-vehicle maker Tesla dropped 4.4% on Thursday, leaving shares down almost 8% for the week.
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority receive frontline chemotherapy and the remainder are treated with osimertinib or afatinib Short time to treatment discontinuation ranging from four to eight months demonstrates clear unmet need for patients with non-classical EGFR mutant NSCLC CAMBRIDGE, Mass., Sept. 14, 2024 (GLOBE NEWSWIRE) -- Black
The Pope blasted Harris's pro-abortion stance and Trump's immigration policies
The death, after being set ablaze, of marathon runner Rebecca Chepetegei shocked the world.
It's praiseworthy that drivers are using their new devices to dob on poor motoring, but will this be the beginning of a slippery slope? asks Adam Lucius.
Joe Biden repeatedly told Sky News correspondent James Matthews to ‘be quiet’ during fiery exchange
The BBC favourite has been embroiled in scandal ahead of its big return to screens for its 20th anniversary
Post-progression outcomes showed significant and sustained improvement for amivantamab plus chemotherapy versus chemotherapy alone1 BEERSE, BELGIUM , Sept. 14, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT®▼ (amivantamab) combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with previously treated non-small cell lung c
RAHWAY, N.J., September 14, 2024--KEYTRUDA plus trastuzumab and chemotherapy OS results as first-line treatment in patients with HER2-positive advanced gastric or GEJ adenocarcinoma.
Nepal has selected “Shambhala” as its Oscar entry in the international feature film category. Directed by Min Bahadur Bham, “Shambhala” – a mystic, sacred realm in Tibetan Buddhism, also an area of significance in Hinduism, which means a place of peace – begins in a Himalayan polyandrous village in Nepal, where pregnant Pema faces scrutiny …
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant segregation of responders in BM+ vs BM- subgroups based on OncoSignature patient selection (p-value = 0.009) ACR-368 endometrial cohort data maturing with all responders still on therapy; mDoR not yet reached (~6 months at time of data-cut) Endometrial cancer now anticipated to be the first tu
Ukraine has repeatedly urged the UK and US to let it fire long-range missiles against targets inside Russia.
NEW YORK, September 14, 2024--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an investigational next-generation ROS1 TKI. The findings will be highlighted in a poster presentation on September 14, 2024, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain
Another huge weekend of boxing in Las Vegas
THE SATURDAY INTERVIEW: The Egot-winning artist has turned his attention to children’s music for the first time with new album, ‘My Favorite Dream’. He chats politics, parenting and pregnancy journeys with Helen Coffey – and explains why social media trolling has lost its power over him and Chrissy Teigen
Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety ProfileBARCELONA, Spain, Sept. 14, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy. In t
It's not unusual to feel less attracted to your partner over time. Here's why that happens — and what to do about it.
EXCLUSIVE: The US star reflected on a decade of success after winning Drag Race in 2014
The global B2B payments market has grown due to rapid automation and digitization, greater international trade, and business sector expansion initiatives. Asia-Pacific emerged as the most significant global B2B payments market, with a 36.7% market revenue share in 2023.Newark, Sept. 14, 2024 (GLOBE NEWSWIRE) -- The global B2B payments market, valued at USD 1,693.60 billion in 2023, is expected to grow at a CAGR of 9.38% from 2024 to 2033. This growth is driven by the rapid adoption of automation
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pre-treated, platinum-resistant ovarian cancer patients T cell fitness gene expression signature in blood is an important parameter of clinical activity for tebentafusp in uveal melanoma and for brenetafusp across different tumor types (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROC
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. 14 September 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta Reports Updated Phase 1 Clinical Data of